Oncology Peer Review On-The-Go: Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer
The conversation with Jun Gong, MD, focused on the evolving relationship between oncologists who treat prostate cancer and genetic counselors.
Jun Gong, MD, discussed his perspective piece from the October issue of the journal ONCOLOGY, titled, “An Evolving Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer.” Gong, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, commented on a review article that was previously examined on this podcast with Alexandra Sokolova, MD, titled, “Germline Testing in Prostate Cancer: When and Who to Test.”
The review article focuses on the treatment implications of germline testing and how it has become more commonplace. Gong’s perspective applauds Sokolova and her colleagues for their work and expands on the necessary relationship between medical oncologists and genetic counselors to effectively treat patients with prostate cancer.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
